FindTrial
Sign In

Erythropoietin for neuroprotection in preterm infants: A longitudinal randomized trial

Longitudinal effects of erythropoietin as a neuroprotective therapy among preterm neonates born less than 32 weeks of gestation: A randomized control trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/068517
Enrollment
54
Registered
2024-06-06
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P073- Preterm [premature] newborn [other]

Interventions

Intervention1: Injection Erythropoietin: Eligible Infants will be divided into two groups (Intervention and control group) by block Randomisation with each block containing 4 infants. Intervention gro

Sponsors

Mahatma gandhi medical college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: preterm less than 32 weeks

Exclusion criteria

Exclusion criteria: 1.Genetically defined disorder 2.Severe congenital malformation unfavorably affecting life span 3.Severe congenital malformation unfavorably affecting neurodevelopment 4. A priory palliative care 5. Intracranial haemorrhage grade 3 or more noticed before dose of Erythropoietin

Design outcomes

Primary

MeasureTime frame
To assess effect of erythropoietin by measuring mental and motor score. To do developmental assessment and neurological assessment of tone, hearing and visualTimepoint: At 6 month and 1 year of corrected gestational age—

Secondary

MeasureTime frame
To prevent Moderate-to-severe neurodevelopmental impairmentTimepoint: At 6 month & 1 year of corrected gestation age—

Countries

India

Contacts

Public ContactDr.K.Karthikeyan

Mahatma Gandhi Medical college and Research institute

drkk3179@gmail.com9443882632

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026